Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/21158
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDulhunty, Joel M-
dc.contributor.authorRoberts, Jason A-
dc.contributor.authorDavis, Joshua S-
dc.contributor.authorWebb, Steven A R-
dc.contributor.authorBellomo, Rinaldo-
dc.contributor.authorGomersall, Charles-
dc.contributor.authorShirwadkar, Charudatt-
dc.contributor.authorEastwood, Glenn M-
dc.contributor.authorMyburgh, John-
dc.contributor.authorPaterson, David L-
dc.contributor.authorStarr, Therese-
dc.contributor.authorPaul, Sanjoy K-
dc.contributor.authorLipman, Jeffrey-
dc.date.accessioned2019-07-10T01:30:04Z-
dc.date.available2019-07-10T01:30:04Z-
dc.date.issued2015-12-01-
dc.identifier.citationAmerican Journal of Respiratory and Critical Care Medicine 2015; 192(11): 1298-305-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/21158-
dc.description.abstractContinuous infusion of β-lactam antibiotics may improve outcomes because of time-dependent antibacterial activity compared with intermittent dosing. To evaluate the efficacy of continuous versus intermittent infusion in patients with severe sepsis. We conducted a randomized controlled trial in 25 intensive care units (ICUs). Participants commenced on piperacillin-tazobactam, ticarcillin-clavulanate, or meropenem were randomized to receive the prescribed antibiotic via continuous or 30-minute intermittent infusion for the remainder of the treatment course or until ICU discharge. The primary outcome was the number of alive ICU-free days at Day 28. Secondary outcomes were 90-day survival, clinical cure 14 days post antibiotic cessation, alive organ failure-free days at Day 14, and duration of bacteremia. We enrolled 432 eligible participants with a median age of 64 years and an Acute Physiology and Chronic Health Evaluation II score of 20. There was no difference in ICU-free days: 18 days (interquartile range, 2-24) and 20 days (interquartile range, 3-24) in the continuous and intermittent groups (P = 0.38). There was no difference in 90-day survival: 74.3% (156 of 210) and 72.5% (158 of 218); hazard ratio, 0.91 (95% confidence interval, 0.63-1.31; P = 0.61). Clinical cure was 52.4% (111 of 212) and 49.5% (109 of 220); odds ratio, 1.12 (95% confidence interval, 0.77-1.63; P = 0.56). There was no difference in organ failure-free days (6 d; P = 0.27) and duration of bacteremia (0 d; P = 0.24). In critically ill patients with severe sepsis, there was no difference in outcomes between β-lactam antibiotic administration by continuous and intermittent infusion. Australian New Zealand Clinical Trials Registry number (ACT RN12612000138886).-
dc.language.isoeng-
dc.subjectantibiotic-
dc.subjectclinical outcome-
dc.subjectintensive care-
dc.subjectpharmacodynamics-
dc.subjectpharmacokinetics-
dc.titleA Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis.-
dc.typeJournal Article-
dc.identifier.journaltitleAmerican Journal of Respiratory and Critical Care Medicine-
dc.identifier.affiliationPharmacy Department, Royal Brisbane and Women’s Hospital, Brisbane, Australiaen
dc.identifier.affiliationPrince of Wales Hospital, Hong Kongen
dc.identifier.affiliationChinese University of Hong Kong, Hong Kongen
dc.identifier.affiliationDepartment of Intensive Care, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationAustralian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, Australiaen
dc.identifier.affiliationDepartment of Intensive Care, Royal Perth Hospital, Perth, Australiaen
dc.identifier.affiliationSchool of Medicine and Pharmacology, University of Western Australia, Perth, Australiaen
dc.identifier.affiliationMenzies School of Health Research, Charles Darwin University, Darwin, Australiaen
dc.identifier.affiliationDepartment of Infectious Diseases, John Hunter Hospital, Newcastle, Australiaen
dc.identifier.affiliationDepartment of Intensive Care Medicine, Royal Brisbane and Women’s Hospital, Brisbane, Australiaen
dc.identifier.affiliationThe Burns, Trauma & Critical Care Research Centre, The University of Queensland, Brisbane, Australiaen
dc.identifier.affiliationInfectious Diseases Unit, Royal Brisbane and Women's Hospital, Brisbane, Australiaen
dc.identifier.affiliationThe University of Queensland Centre for Clinical Research, Brisbane, Australiaen
dc.identifier.affiliationCritical Care and Trauma Division, The George Institute for Global Health, Sydney, Australiaen
dc.identifier.affiliationSt. George Clinical School, University of New South Wales, Sydney, Australiaen
dc.identifier.affiliationDepartment of Intensive Care, Blacktown Hospital, Blacktown, Australia-
dc.identifier.affiliationClinical Trials and Biostatistics Unit, QIMR Berghofer Medical Research Institute, Brisbane, Australia-
dc.identifier.doi10.1164/rccm.201505-0857OC-
dc.identifier.orcid0000-0002-4524-0548-
dc.identifier.orcid0000-0001-6218-435X-
dc.identifier.orcid0000-0003-0848-7194-
dc.identifier.orcid0000-0002-1650-8939-
dc.identifier.pubmedid26200166-
dc.type.austinComparative Study-
dc.type.austinJournal Article-
dc.type.austinMulticenter Study-
dc.type.austinRandomized Controlled Trial-
dc.type.austinResearch Support, Non-U.S. Gov't-
local.name.researcherBellomo, Rinaldo
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptIntensive Care-
crisitem.author.deptData Analytics Research and Evaluation (DARE) Centre-
crisitem.author.deptIntensive Care-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

22
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.